BioSpace News Archive

Bluejay Diagnostics, Inc. today announced that the Company’s Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-8 (the “Reverse Stock Split”).

Amarna Therapeutics, a privately-held biotechnology company focused on developing transformative gene therapies for a range of rare and prevalent genetic diseases, including Type 1 Diabetes Mellitus, is pleased to announce the formation of its new Scientific Advisory Board. The newly established SAB consists of seven distinguished international scientific opinion leaders.

Takeda announced topline data from its SKYLINE and SKYWAY studies. SKYLINE was a multicenter, randomized, double-blind Phase 3 study that evaluated soticlestat plus standard of care versus placebo plus standard of care in patients with refractory Dravet syndrome.1 Soticlestat narrowly missed the primary endpoint of reduction from baseline in convulsive seizure frequency as compared to placebo.

Keros Therapeutics, Inc. announced that it presented additional data from its two ongoing Phase 2 clinical trials of elritercept, one in patients with very low-, low-, or intermediate-risk myelodysplastic syndromes and one in patients with myelofibrosis, at the 29th Annual Hybrid Congress of the European Hematology Association, held in person in Madrid, Spain and virtually from June 13 through 16, 2024.

Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, announced Ian Taylor, Ph.D. has been promoted to President of Research and Development and Angela Cacace, Ph.D. has also been promoted and will succeed Dr. Taylor as Chief Scientific Officer of the company.

At the recent European League Against Rheumatism Congress in Vienna, Austria, Nanjing Leads Biolabs Co., Ltd. delivered an oral presentation on its highly innovative therapeutic candidate LBL-047.

Peijia Medical announced the publication of its audited financial results for the year ended December 31, 2023 (“the period”) on June 16, 2024.

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced the presentation of new data from an investigator-led analysis of the Phase 2 111-205 study, which demonstrate that children with achondroplasia treated with VOXZOGO® experienced increases in bone length while maintaining bone strength.

SELLAS Life Sciences Group, Inc. today announced a positive review of the ongoing Phase 3 REGAL clinical trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML) by the Independent Data Monitoring Committee (IDMC).

The International Society on Thrombosis and Haemostasis announces that all ISTH 2024 Congress abstracts are available online, including late-breakthrough abstracts, to give a detailed glimpse into the posters, presentations and plenaries that will be presented at the Congress in Bangkok, Thailand.